FDA PEDIATRIC EXCLUSIVITY WORKING GROUP SEEKS INPUT ON DEFINITION OF DRUGS ELIGIBLE FOR EXCLUSIVITY; GROUP INCLUDES REPRESENTATIVES FROM ALL CDER REVIEW DIVISIONS
Executive Summary
FDA is seeking input on how to define drugs that "may produce health benefits" in pediatric patients as a precondition for granting exclusivity under the FDA Modernization Act.